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Retinal Ganglion Cells stained with brn3a (red)  in retinal explants. Cell nuclei 
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“Os dias prósperos não vêm por acaso, são granjeados, como as searas, com muita 
fadiga e com muitos intervalos de desalento.” 
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Resumo 
O glaucoma é a segunda causa de cegueira a nível mundial e é caracterizado pela 
perda progressiva de células ganglionares da retina (CGR). A pressão intraocular 
(PIO) é considerada o maior fator de risco para desenvolver glaucoma, e a redução 
da PIO é atualmente a única terapia utilizada. Contudo, apesar de um controlo 
adequado da PIO uma percentagem significativa de doentes continua a perder visão. 
Várias evidências têm demonstrado que a neuroinflamação tem um papel importante 
na patogénese do glaucoma. Em situações de neuroinflamação, as células da microglia 
ficam ativadas e libertam mediadores inflamatórios, os quais podem iniciar e 
perpetuar processos degenerativos e a morte das CGR. 
A enzima hidrolase de ácidos gordos com um grupo amida (do inglês fatty acid 
amide hydrolase, FAAH) é considerada o mediador primário da hidrólise dos 
endocanabinóides, tais como anandamida (AEA), oleoiletanolamina (OEA), e 
palmitoiletanolamina (PEA). O aumento da resposta aos endocanabinóides pode ser 
alcançado com a inibição da atividade da FAAH, bem como através da inibição do seu 
transportador. Foi descrito que o aumento local dos níveis de endocanabinóides, 
particularmente da AEA, pode complementar eficazmente estratégias 
neuroprotetoras para o tratamento de doenças degenerativas da retina, como o 
glaucoma. Além disso, tendo em conta as propriedades dos endocanabinóides como 
hipotensores oculares, e os seus efeitos neuroprotetores e anti-inflamatórios, os 
inibidores da FAAH têm potencial para reduzir a PIO e proteger as CGR, reforçando 
assim a sua relevância para o tratamento do glaucoma. 
Neste estudo, pretendeu-se avaliar o potencial efeito de um inibidor da FAAH 
(URB597) na diminuição da PIO num modelo de hipertensão ocular (cauterização das 
veias episclerais – CVE). Além disso, pretendeu-se investigar, pela primeira vez, os 
potenciais efeitos neuroprotetores e anti-inflamatórios do URB597 num modelo de 
pressão hidrostática elevada (PHE), com o objetivo de mimetizar uma situação de 
PIO elevada, em explantes de retina de rato. 
Em animais submetidos a CVE, a PIO aumentou significativamente, durante pelo 
menos 7 dias. A administração do URB597 diminuiu significativamente a PIO, e este 
efeito pareceu ter sido mediado pela ativação dos recetores dos endocanabinóides 
do tipo CB1. A atividade da FAAH foi fortemente inibida pelo URB597 em culturas 
organotípicas de retina. Além disso, o composto URB597 aumentou os níveis de AEA, 
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OEA e PEA nestas culturas. A exposição de explantes de retina a PHE reduziu 
significativamente a sobrevivência das CGR. O tratamento com URB597 inibiu a 
diminuição do número de CGR. Contudo o efeito protetor do URB597 pareceu não 
ter sido mediado pela ativação dos recetores CB1. Além disso, o composto URB597 
inibiu o aumento da imunoreatividade da isoforma indutível da sintase do monóxido 
de azoto (do inglês inducible nitric oxide synthase, iNOS) em células da microglia, 
induzida pela PHE em explantes de retina. No entanto, uma vez mais, o efeito 
inibitório do URB597 não pareceu ter sido mediado pelo recetor CB1. 
Em conclusão, os resultados apresentados nesta tese indicam claramente que a 
enzima FAAH representa um potencial alvo terapêutico num contexto de glaucoma, 
que vale a pena investigar, uma vez que a inibição da FAAH tem potencial para 
diminuir a PIO, para controlar a neuroinflamação e para proporcionar 
neuroprotecção contra a degenerescência das CGR. 
 
Palavras-chave: Glaucoma, pressão intraocular, endocanabinóides, inibidor da 
FAAH, neuroprotecção da retina, neuroinflamação, cauterização das veias episclerais, 
pressão hidrostática elevada, recetor CB1. 
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Abstract 
Glaucoma is the second leading cause of blindness in the world and is characterized 
by progressive loss of retinal ganglion cells (RGCs). Elevated intraocular pressure 
(IOP) is considered the primary risk factor for the development of glaucoma and 
lowering IOP is the only clinical therapy available. However, some patients continue 
to lose vision despite successful IOP control. It has been shown that 
neuroinflammation plays an important role in the pathogenesis of glaucoma. During 
neuroinflammatory events, microglial cells become activated and release pro-
inflammatory mediators, which in turn can initiate and perpetuate degenerative 
processes and RGC death. 
The enzyme fatty acid amide hydrolase (FAAH) is thought to be the primary 
mediator of the hydrolysis of released endocannabinoids, such as anandamide (AEA), 
oleoiletanolamine (OEA), and palmitoiletanolamine (PEA). Enhancement of 
endocannabinoid responses can be achieved with inhibition of FAAH activity, as well 
as through inhibition of its endocannabinoid transporter. It was described that 
increasing local endocannabinoid levels, particularly AEA, may be an effective 
supplement to the arsenal of neuroprotective strategies for retinal degenerative 
diseases, such as glaucoma. Moreover, taking into account the ocular hypotensive 
properties of endocannabinoids, in addition to its neuroprotective and anti-
inflammatory effects, FAAH inhibitors have the potential to decrease IOP, thereby 
strengthening its relevance to treat glaucoma, protecting RGCs against degeneration.  
In this study, we aimed to assess the potential effect of a FAAH inhibitor (URB597) 
in decreasing IOP in a model of ocular hypertension (episcleral vein cauterization - 
EVC). In addition, another goal was to investigate, for the first time, the potential 
neuroprotective and anti-inflammatory effects of URB597 in a model of elevated 
hydrostatic pressure (EHP), mimicking elevated IOP, in rat retinal explants.  
In animals submitted to EVC, the IOP was significantly increased, at least for 7 
days. The administration of URB597 significantly decreased IOP, and this effect 
seemed to be partially mediated by CB1 receptor activation. The activity of FAAH 
was strongly inhibited by URB597 in retinal organotypic cultures. Moreover, URB597 
increased the levels of AEA, OEA, and PEA in these cultures. Exposure of retinal 
explants to EHP significantly reduced RGC survival. Treatment with URB597 inhibited 
the decrease in the number of RGCs, but this protective effect did not seem to be 
mediated by the activation of CB1 receptors. In addition, URB597 inhibited the 
increase of iNOS immunoreactivity in microglial cells induced by EHP exposure in 
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retinal explants, but the CB1 receptor did not seem to mediate this inhibitory effect 
of URB597. 
In summary, our results clearly show that FAAH enzyme represents a potential 
therapeutic target worth to investigate in the context of glaucoma, once FAAH 
inhibition has the potential to decrease IOP, control neuroinflammation, and provide 
neuroprotection against RGC degeneration. 
 
Keywords: Glaucoma, intraocular pressure, endocannabinoids, FAAH inhibitor, 
retinal neuroprotection, neuroinflammation, episcleral vein cauterization, elevated 
hydrostatic pressure, CB1 receptor. 
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1. Introduction 
 
1.1. Anatomy of the Eye 
The eye is an important organ that allows gathering information about the 
surrounding world. This organ is a highly specialized and organized structure that 
receives the light and transduces this information into electrical signals, which are 
processed and converted into visual images in the brain (Purves, 2004). 
The outermost layer of the eye is composed by the sclera and cornea (Fig. 1). The 
sclera is a white fibrous and opaque tissue that helps to confer shape and protection 
to the internal structures of the eye. At the front of the eye, this opaque layer 
becomes the cornea, a transparent avascular tissue that allows the input of light into 
the eye causing reflection or refraction of the light that enters (Kolb, 1995;Purves, 
2004).  
Inner to the sclera and cornea is the uveal tract, formed by three distinct 
structures, the choroid, ciliary body and iris. Choroid is rich in blood vessels and its 
main function is the nourishment of the outer layers of the retina. The iris is the most 
anterior component of the uveal tract, the coloured portion of the eye that can be 
seen through the cornea. It contains two sets of muscles that control the size of the 
pupil so that more or less light is allowed to enter the eye. The ciliary body has a 
muscular component attached to the lens by zonule fibres, which enables the lens to 
change shape during accommodation, and a vascular component which produces the 
aqueous humour that fills the anterior and posterior chambers of the eye. Aqueous 
humour is produced by the ciliary processes in the posterior chamber (between the 
iris and the lens) and flows into the anterior chamber (between the cornea and the 
iris) through the pupil. The rates of aqueous humour production and drainage must 
be balanced to ensure a constant intraocular pressure (IOP). The drainage of the 
aqueous humour is processed generally through the trabecular meshwork 
(Schelmm´s channel) (Kolb, 1995;Purves, 2004).  
The innermost layer of the eye is formed by the retina, a light sensitive tissue that 
has the function of photoreception and transmits impulses to the brain. In addition 
to anterior and posterior chambers, there is a third chamber inside the eye, the 
vitreous chamber, located between the lens and the retina. This chamber is filled with 
a gelatinous substance mainly composed by collagen fibres. The vitreous humour is 
responsible for maintaining the eye integrity  (Kolb, 1995;Purves, 2004). 
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Figure 1 - Anatomy of the human eyeball (adapted from: 
http://en.excimerclinic.ru/press/stroenieglaza). 
 
1.2. The Retina 
 
1.2.1. Retinal Structure 
The retina, despite its peripheral location, is part of the central nervous system 
(CNS) and it is organized in eight different layers (Fig. 2).  The retinal pigment 
epithelium (RPE) is the outermost one and its main role is renewing photoreceptor 
photopigments and phagocytosing the photoreceptor disks, being this interaction 
essential for visual function. Inner to RPE is the layer composed by photoreceptor 
outer segments (OS) which contains the visual photopigments. The cell bodies of the 
photoreceptors (cones and rods) are in the inner segments (IS), and form the outer 
nuclear layer (ONL), while the synapses between photoreceptors, bipolar, and 
horizontal cells occurs in the outer plexiform layer (OPL). The inner nuclear layer 
(INL) is composed by the cell bodies of bipolar, amacrine, and horizontal cells. The 
synapses between bipolar, amacrine, and retinal ganglion cells (RGCs) take place in 
the inner plexiform layer (IPL). The cell bodies of RGCs and some displaced amacrine 
cells form the ganglion cell layer (GCL). The RGC axons are responsible for carrying 
the visual information to the brain, and constitute the nerve fiber layer (NFL) (Kolb, 
1995;Purves, 2004). 
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Figure 2- Anatomy of the retina showing all the neuronal cell types. RPE - retinal pigment 
epithelium; OS - photoreceptor outer segments; ONL - outer nuclear layer; OPL -  outer plexiform 
layer; INL - inner nuclear layer; IPL - inner plexiform layer; GCL - ganglion cell layer; NFL- nerve fiber 
layer (adapted from (Purves, 2004)). 
 
1.2.2. Retinal Neurons 
The neuronal component of the retina is composed by five different types of 
neuronal cells: photoreceptors, bipolar cells, horizontal cells, amacrine cells, and 
RGCs (Fig.2). 
In the vertebrate retina there are two types of photoreceptors: rods and cones. 
Both types have an outer segment composed of membranous disks containing light-
sensitive photopigment that lies adjacent to the RPE, and an IS that contains the cell 
nucleus and gives rise to synaptic terminals contacting bipolar and horizontal cells 
(Purves, 2004). Two or three types of cone photoreceptor and a single type of rod 
photoreceptor are present in the mammalian retina, and its distribution in the retina 
is very important for visual processing. Rods contain the visual photopigment 
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rhodopsin, allowing for high light sensitivity, essential for vision under dark-dim 
conditions at night. In contrast, cones contain cone opsins as their visual 
photopigments. The cone opsins are responsible for bright light and coloured vision 
(Kolb, 1995). Absorption of light by the photopigments initiates a cascade of events, 
which lead to hyperpolarization of photoreceptor membrane, and consequently the 
decrease of neurotransmitter (glutamate) released by the photoreceptor synapses 
onto the cells they contact (Purves, 2004). 
 
Bipolar cells are the interlocutors between the light transduction of 
photoreceptors and amacrine cells and RGCs. In human retina there are eleven 
different bipolar cell types, ten of which contact cones and one type contacts rods 
(Kolb, 1995). These cells, based on how they react to glutamate released from 
photoreceptors, can be classified into ON- and OFF-type bipolar cells, distinguishable 
by the type of glutamate receptor they express. The OFF-type bipolar cells express 
ionotropic glutamate receptors and are hyperpolarized by light. ON-type bipolar cells 
express metabotropic glutamate receptors and are depolarized by light (Kolb, 
1995;Purves, 2004). 
 
The RGCs are the final output neurons of the retina, collecting visual signals from 
bipolar and amacrine cells. RGCs can also be divided into ON- and OFF-centre, 
according to the bipolar cell types they contact within their receptive field. The 
number of ON- and OFF-centre RGC types in the retina is approximately the same, 
and usually the receptive field of neighbour cells overlap. This distribution allows the 
same retinal point to be analysed by several ON- and OFF-RGCs (Purves, 2004). 
These two types of RGCs are distinguished by their firing rate when they are 
stimulated by a small spot of light in the centre of their receptive field. When the 
centre of an OFF-centre RGC is exposed to light it hyperpolarizes, decreasing their 
discharge rate. Conversely, they depolarize when the surround receptive field is 
exposed to light, increasing their firing rate. ON-centre RGCs have the opposite 
response. They become activated when the centre is exposed to light and inactive 
when the surround is stimulated. Thus, OFF-centre RGCs increase their discharge 
rate to luminance decrements in the receptive field, whereas ON-centre RGCs 
increase their discharge rate to luminance increments in the receptive field (Kolb, 
1995;Purves, 2004). 
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Horizontal cells are interneurons in the retina and modulate signal transmission 
between photoreceptors and bipolar cells (Kaneda, 2013). Horizontal cells’ processes 
allow lateral interactions between photoreceptors and bipolar cells, which maintain 
the visual system’s sensitivity to luminance contrast over a wide range of light 
intensities (Kolb, 1995;Purves, 2004). 
 
Amacrine cells are interneurons, present in the INL and GCL that modulate the 
signal transmission between bipolar cells and RGCs. There are more than 20 classified 
subtypes of amacrine cells, and according to the subtype, they have different 
contributions for the processing of visual elements, such as contrast, colour, 
brightness, and movement (Purves, 2004;Kaneda, 2013).  
 
1.2.3. Retinal Glial Cells 
Similarly to other CNS regions, the retina is also composed by glial cells. There 
are three types of glial cells in the retina: Müller cells, astrocytes and microglia, which 
are responsible for neuro-supporting and immunocompetent defence (Langmann, 
2007).  
 
Müller cells are the main glial cell type of the retina, spanning from the vitreal 
surface to subretinal space and covering all retinal layers. Müller cells are major 
supporting cells in regulating physiological and pathological responses of neurons and 
retinal vasculature. These cells have an important role in metabolism and protection 
providing trophic factors, removing metabolic wastes, controlling ion and water 
homeostasis and extracellular space volumes, participating in visual cycles, releasing 
neurotransmitters, regulating blood-retinal barrier (BRB) function, and modulating 
innate immunity (Reichenbach and Bringmann, 2013). 
 
Astrocytes are the major glial cell type found at the optic nerve head (ONH) and 
at NFL, and undertake some essential functions related to the CNS homeostasis. In 
response to injuries, astrocytes proliferate, change their morphology, and increase 
glial fibrillary acidic protein (GFAP) expression; this process is designated astrogliosis 
(Kolb, 1995;Chong and Martin, 2015). Astrocytes are also part of the BRB, having a 
close association with retinal vessels and regulating its properties. Moreover, 
astrocytes contribute to neuronal nutrition, providing glucose, and also contribute to 
the regulation of extracellular potassium levels and metabolism of neurotransmitters 
such as GABA (Kolb, 1995). 
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Microglial cells are the resident macrophages in the CNS and they have an 
important role in the surveillance of the microenvironment. In healthy conditions, 
microglial cells acquire a characteristic ramified morphology extending long thin 
processes; this stage has been named “resting” state (Kettenmann et al., 2011). In 
response to various stimuli associated with aging, neurodegeneration, or injury, 
microglia turn into the activated state, an effector phenotype, in which they migrate 
to the site of injury, proliferate, and phagocytose cells and cellular compartments 
(Bosco et al., 2011;Kettenmann et al., 2011). Upon activation, microglial cells release 
cytokines, chemokines, nitric oxide (NO), and reactive oxygen species (ROS), which 
could be detrimental or beneficial to the neighbouring cells (Harry, 2013). Thus, 
microglial cells are indispensable in the adult CNS as stabilizers and modulators of 
tissue homeostasis under physiological or pathological conditions (Kierdorf and Prinz, 
2013). 
In the retina, microglial cells are mainly located in the inner vascularized regions, 
i.e. the NFL, GCL, OPL and IPL, while they are not frequent in the INL and absent in 
the ONL (Santiago et al., 2014). In a healthy retina, microglial cells also play important 
roles in tissue surveillance and intercellular communication by continuous and 
dynamic behavior (Lee et al., 2008). In the resting state, microglial cells mainly 
populate the plexiform layers, and actively survey their microenvironment with 
extremely motile processes and protrusions (Fig. 3A) (Li et al., 2015). In this state 
microglial cells also phagocytose the cellular debris from neurons in the INL and GCL 
(Langmann, 2007). In retinal insult situation, such as optic nerve damage, inflammation, 
light injury, intoxication, hereditary diseases or metabolic disturbance, microglia are 
activated immediately changing their morphology (Fig. 3B) (Saijo and Glass, 2011). 
Therefore, in the effector phase (Fig. 3C), microglia and/or recruited blood-derived 
precursors migrate to the nuclear layers and the subretinal space, where they engulf 
dying cell corpses (Karlstetter et al., 2010). 
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Figure 3 - Schematic representation of three common phases of microglial activity in the 
retina. (A) In the normal retina, resident microglia mainly populate the plexiform layers. With their 
long protrusions they continuously scan their environment, phagocytose cell debris and secrete a 
variety of supporting factors including neurotrophins. (B) Various different insults leading to abnormal 
cell functions or degeneration in the RPE, the photoreceptor layer, and the GCL rapidly alert microglia. 
(C) Resident microglia and/or recruited blood-derived precursors migrate to the lesion sites, where 
they transform into amoeboid full-blown phagocytes. These effector cells may be protective or 
detrimental depending on their immunological phenotype and the local cytokine milieu. RPE - retinal 
pigment epithelium, ONL - outer nuclear layer, OPL - outer plexiform layer, INL - inner nuclear layer, 
IPL - inner plexiform layer, GCL - ganglion cell layer (adapted from (Karlstetter et al., 2010). 
 
1.2.4. Blood Vessels 
The retina has the higher oxygen consumption per weight of human tissue. 
Therefore, it needs a complex vascular system to provide oxygen and nutrients to 
the highly metabolically active neural retina. To accomplish this metabolic requisite, 
the retina is supplied by two different sources of blood vessels, the central retinal 
artery and the choroidal blood vessels.  The central retinal artery gives rise to 
capillaries that innervate the inner retina, while the choroidal blood vessels supply 
photoreceptors in the outer retina (Klaassen et al., 2013). 
In order to protect the retina from potentially harmful molecules in the 
circulation, the BRB is divided into inner BRB (iBRB) and outer BRB (oBRB) (Fig. 4). 
The iBRB is formed by the tight junctions of retinal capillary endothelial cells, which 
are surrounded by pericytes, astrocytes, Müller cells, microglia and neurons. The 
oBRB consists of the tight junctions of RPE cells, and is responsible for the 
maintenance of the homeostasis of the outer retina. The iBRB and oBRB tight junction 
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proteins consist mainly of occludin, claudins, zonula ocludens proteins, and junctional 
adhesion molecules (Cunha-Vaz et al., 2011;Zhang et al., 2014).  
 
 
 
Figure 4 - Scheme of the BRB. The retinal cell layers are presented, as follows: RPE - retinal 
pigment epithelium; OS - photoreceptor outer segments; OLM - outer limiting “membrane”; ONL - 
outer nuclear layer; OPL - outer plexiform layer; INL - inner nuclear layer; IPL - inner plexiform layer; 
GCL - ganglion cell layer;  NFL - nerve fiber layer; ILM - inner limiting “membrane” (adapted from 
(Hosoya, 2008)). 
 
1.3. Glaucoma 
Glaucoma refers to several optic neuropathies associated with degeneration of 
RGCs and their respective axons, leading to slow progressive visual field loss (Fig 5). 
Glaucoma is considered the second leading cause of blindness throughout the world. 
In 2010, at least 60.5 million people suffered from glaucoma worldwide and it is 
expected to increase up to 80 million by 2020 (Van de Velde et al., 2015). 
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Figure 5 – Images representative of how glaucoma affects vision at the peripheral fields, 
in patients at different stages of the disease (adapted from 
http://seaviewoptometry.com/eye_care/glaucoma-prevention.html).  
 
The pathology of glaucoma is not entirely elucidated, although it is known that 
there are multiple risk factors such as genetic mutations, ethnicity, age, and increased 
IOP. A basal IOP is needed to maintain the shape and homeostasis of the eye, and is 
regulated by aqueous humour production in the ciliary bodies (To et al., 2002) and 
drainage through two mechanisms: conventional outflow, which is through trabecular 
meshwork and Schlemm’s canal, and uveoscleral outflow (Fig. 6) (Doucette et al., 
2015). 
 
Figure 6 - Scheme of the normal outflow of the aqueous humour. Outflow of the aqueous 
humour occurs by two ways: trabecular outflow (A) and uveoscleral outflow (B). The aqueous humour 
formation occurs in the ciliary bodies (C) (adapted from http://www2.cfpc.ca/cfp/2005/Sep/vol51-sep-
cme-3_fr.asp). 
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Glaucoma is also associated with a typical appearance of structural damage at the 
optic nerve head (ONH), seen as excavation of ONH, and sectoral retinal nerve fiber 
layer defects (Chang and Goldberg, 2012) (Fig. 7).  
Since increased IOP is the major risk factor to develop glaucoma, the treatment 
of this disease is mainly directed towards lowering IOP, although many patients 
present signs of progression of this neuropathology despite well-controlled IOP (Van 
de Velde et al., 2015). In fact, RGC degeneration can be caused by other factors such 
as activation of the glial cells in response to glaucomatous stress, which exhibit 
important links of this pathology to different components of the immune system 
(Tezel, 2011). 
 
Figure 7 - Scheme of the excavation of ONH during the progression of glaucoma. (A ) 
Normal ONH; (B) ONH in an early stage of glaucoma; (C) ONH in an advanced stage of glaucoma 
(adapted from http://www.dreyeins.com/tests-for-glaucoma.php). 
 
1.3.1. Glaucoma and Neuroinflammation  
In the pathogenesis of glaucoma, neuroinflammation has been described as an 
important player in disease progression, by activating glial cells that initiate an 
inflammatory response (Madeira et al., 2015a).   
Glial cells have a high level of plasticity which allows them to rapidly respond to 
any homeostatic imbalance by exhibiting the active phenotype with altered cell 
morphology and expression of cell markers (Tezel, 2011). Namely, microglial cells in 
glaucomatous conditions have shown alterations in morphology, gene expression, cell 
proliferation, cell adhesion, and immune response, compatible with a reactive 
phenotype. (Karlstetter et al., 2010;Madeira et al., 2015a). When microglial reactivity 
becomes excessive or prolonged, it may lead to chronic inflammation, by an excessive 
production of pro-inflammatory and neurotoxic factors such as tumor necrosis factor 
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(TNF), interleukin-6 (IL-6), interleukin-1ß (IL-1 ß), NO, endothelin, complement 
proteins and superoxide, with severe pathological effects potentially resulting in RGC 
loss (Karlstetter et al., 2010;Almasieh et al., 2012). 
In several animal models of glaucoma, it has been described that microglia, Müller 
cells and ONH astrocytes play critical roles in glaucomatous neurodegeneration 
(Chong and Martin, 2015). In DBA/2J mice, which are transgenic mice with age-related 
ocular hypertension, microglial activation has been correlated with the loss of RGCs; 
reducing microglial activation has been suggested to increase RGC viability 
(Fernandes et al., 2015). 
In previous studies in our group, using retinal organotypic cultures, challenged with 
either elevated hydrostatic pressure (EHP) or lipopolysaccharide (LPS), microglial 
cells are activated and this is paralleled by an increase in the expression and release 
of the pro-inflammatory cytokines IL-1ß and TNF. Moreover, adding anti-IL-1β and 
anti-TNF antibodies to the culture medium prevents RGC death triggered by EHP or 
LPS, indicating that RGC death is caused by microglia reactivity and particularly by 
pro-inflammatory cytokines (Madeira et al., 2015b).  
Moreover, the cross-talk between microglia and RGCs, as well as other types of 
retinal glia may plays an important role determining the glial behavior in a disease 
context, as glaucoma. Thus, targeting certain aspects of glial signalling in the retina 
could be a therapeutic strategy with great potential for future clinical applications 
(Chong and Martin, 2015). 
 
1.3.2. Glaucoma and Neuroprotection 
Glaucoma is a multifactorial degenerative disease, with complex genetic and 
environmental factors involved in its pathogenesis (Baltmr et al., 2010). As previously 
mentioned, RGC death is a hallmark of glaucoma, in which several mechanisms might 
be involved. IOP is considered the main direct inducer of RGC stress and apoptosis, 
although damage to RGCs may occur in the presence of normal IOP. 
Several other pathogenic processes have been identified such as retinal ischemia, 
glial cell activation, mitochondrial dysfunction, protein misfolding, neurotrophin 
deprivation, oxidative stress, excitotoxicity due to raised extracellular levels of 
glutamate, and all may induce apoptotic RGC death in glaucoma (Baltmr et al., 
2010;Qu et al., 2010;Chen et al., 2015). Therefore, all these processes may be targeted 
in order to afford neuroprotection and prevent RGC loss independent of IOP 
elevation (Chen et al., 2015). 
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1.3.3. Animal Models of Glaucoma  
There are several animal models of glaucoma, including genetic models (e.g. 
DBA/2J mice) and inducible models of IOP elevation such as: microbead injections in 
the anterior chamber (Sappington et al., 2010;Morgan and Tribble, 2015), 
glucocorticoid-induced IOP elevation (Overby and Clark, 2015), episcleral vein 
cauterization (EVC) (Shareef et al., 1995;Urcola et al., 2006), and saline injection in 
the episcleral veins (Morrison et al., 1997).  
In the microbeads model described by Sappington (2010), the IOP increases 
around 30% in rodents, comparing with the control eyes, and this increase is 
consistent during 4–5 weeks (Sappington et al., 2010). In this model, there is 
approximately a 20% loss of ganglion cell axons in rats and mice. In the saline injection 
in the episcleral veins model, described by Morrison (1997), IOP is elevated from 7 
to 28 mm Hg, leading to axonal damage, sclerosis of the trabecular meshwork (TM) 
and optic nerve damage, which is characteristic of glaucoma (Morrison et al., 1997). 
In the glucocorticoid-induced ocular hypertension model, IOP increases in rats during 
2 to 4 weeks, after the eye topical administration of dexametasone, which is a 
glucocorticoid, every day until 4 weeks. In this model occurs an increase in TM  
thickness and a decrease in TM cell number, occurring also a decrease in the thickness 
and in the cell number in the RGC layer (Overby and Clark, 2015). Overall, the main 
goal of these models is to study RGC degeneration and other related complications 
triggered by chronic ocular hypertension. Unfortunately, all these models have some 
disadvantages and sometimes are difficult to reproduce and to induce a consistent 
and sustained IOP increase. 
EVC glaucoma model consists in cauterizing the episcleral veins of the eye, and 
thus blocking the outflow of the aqueous humour through the Schlemm’s channel and 
by the uveoscleral pathway (Urcola et al., 2006). By this way, IOP increases and 
induces retinal cell death, namely RGC death. It has been described that in rats 
submitted to EVC model, not only occurs RGC degeneration, but also amacrine and 
bipolar cells damage; the loss of these cells causes changes in visual direction 
selectivity processing that could also be associated with glaucoma (Danias et al., 
2006;Hernandez et al., 2009). In addition, it has been reported that RGC death, 
induced by EVC, activates astrocytes and Müller cells. Astrogliosis also may potentially 
exacerbate the glaucomatous process by overexpressing toxins, producing a direct 
toxic effect on RGCs (Hernandez et al., 2010;Vecino et al., 2015). Moreover, IOP 
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elevation caused by EVC model triggers an inflammatory response, activating 
microglia around ONH, which express proinflammatory cytokines (Roh et al., 2012).  
As described above, several animal models of RGC death and elevated IOP have 
been developed to try to unveil the mechanisms behind glaucomatous disease. In 
addition, in vitro models of EHP have been developed to evaluate cell responses at 
several timepoints and pressure levels (15 mmHg to 100 mmHg above atmospheric 
pressure) (Agar et al., 2000;Agar et al., 2006;Sappington et al., 2009;Tok et al., 2014). 
In the model of EHP, that we established in our laboratory, hydrostatic pressure levels 
are increased 70 mmHg above atmospheric pressure (Madeira et al., 2015b). In fact, 
in the case of elevated IOP, some tissues in the eye are exposed to increased 
hydrostatic pressure: the retinochoroidal complex experiences increased hydrostatic 
pressure from within the vitreal chamber and from the suprachoroidal space, and 
RGC axons in the ONH are exposed continuously to increased hydrostatic pressure 
(Sappington et al., 2009). 
In models of EHP, it has been shown the induction of neuronal cell apoptosis, 
namely in RGCs (Madeira et al., 2015b), and oxidative stress processes (Agar et al., 
2000;Agar et al., 2006;Tok et al., 2014). Moreover, submitting retinas or eye cup 
preparations to EHP induces glial cell activation, GFAP expression in Müller cells, and 
retinal axonal and Müller cell swelling (Ishikawa et al., 2010;Ishikawa et al., 2011). In 
the model that we used, which is similar to Sappington model, the increase of 70 
mmHg above atmospheric pressure for 24h induces microglia reactivity and RGC 
death (Sappington et al., 2009;Sappington et al., 2010;Madeira et al., 2015a). 
 
1.4. Cannabis and Endocannabinoids 
Cannabis sativa, the marijuana plant (Fig. 8), has as major active component, Δ9-
tetrahydrocannabinol (THC), which is the main responsible for the psychoactive 
effects of cannabis consumption. Besides this effect, THC also produces numerous 
beneficial effects, including analgesia, appetite stimulation, nausea reduction and 
reduction of IOP. Due to these properties, cannabis has been used in medicine for 
decades (Pacher et al., 2006;Pertwee, 2006). In addition, THC mimics the action of 
endogenous fatty acid derivatives, namely endocannabinoids (Yazulla, 2008).  
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Figure 8 - Cannabis sativa, the marijuana plant (found in 
http://www.medscape.com/viewarticle/837011). 
 
Endocannabinoids are neuromodulators in the CNS and act through two types of 
cannabinoid receptors: CB1 and CB2. The most investigated endocannabinoids are N-
arachidonoylethanolamide (anandamide or AEA) and 2-arachidonoyl glycerol (2-AG), 
although many others are being studied, as palmitoylethanolamide (PEA) and 
oleoylethanolamide (OEA), 2-arachidonylglyceryl ether (noladin ether), 
oarachidonoylethanolamine (virodhamine) and N-arachidonoyldopamine (Fig. 9).   
Figure 9 – Chemical structures of the N-acylethanolamines: AEA – anandamide; PEA - 
palmitoylethanolamide; OEA – oleoylethanolamide; 2-AG - 2-arachidonoyl glycerol (adapted from 
(Joosten et al., 2010) and from (Baur et al., 2013)).  
 
Furthermore, they belong to a very large group of bioactive lipids, which function as 
neuromodulators and immunomodulators. There is also evidence that 
endocannabinoids serve as retrograde synaptic messengers in the CNS (Pertwee, 
2005;Vaughan and Christie, 2005;Yazulla, 2008).  
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Endocannabinoids have a role in neuroplasticity in several conditions, including 
pain, stroke, cancer, obesity, osteoporosis, fertility, neurodegenerative diseases, like 
glaucoma, and inflammatory diseases, among others (Yazulla, 2008). Moreover, 
several studies have demonstrated that endocannabinoids can have a neuroprotective 
effect in retinal cells (Nucci et al., 2007). Also, it has been demonstrated that the 
endocannabinoid system is highly activated during CNS inflammation and that the 
endocannabinoid AEA protects neurons from inflammatory damage (Eljaschewitsch 
et al., 2006;Hernangómez et al., 2014).  
 
1.4.1. Endocannabinoid System 
The endogenous cannabinoid system includes endocannabinoids, cannabinoid 
receptors, and the proteins involved in their biosynthesis, metabolism, and release. 
The two main endocannabinoids in the system are AEA and 2-AG, which are 
produced via a phospholipid-dependent pathway, released, and then taken up by cells 
via diffusion through the plasmatic membrane. Endocannabinoids are metabolized 
mostly via intracellular enzymatic hydrolysis. After their production, 
endocannabinoids are not accumulated into synaptic vesicles and are metabolized by 
fatty acid amide hydrolase (FAAH), in the case of AEA, and by monoacylglycerol lipase 
(MAGL) and FAAH, in the case of 2-AG (Di Marzo et al., 2005) (Fig. 10). 
Figure 10 - Endocannabinoid system in pre- and postsynaptic neurons. The presynaptic 
terminal is located in the top, whereas the postsynaptic neuron is located in the bottom. The FAAH 
converts AEA in ethanolamide and arachidonic acid. The MAGL converts 2-AG into glycerol and 
arachidonic acid. FAAH - fatty acid amide hydrolase; EMT - endocannabinoid membrane transporter; 
MAGL - monoacylglyceride lipase (adapted from (Pacher et al., 2006)). 
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The processes responsible for the production, membrane transport and enzymatic 
inactivation of endocannabinoids are all potential pharmacological targets, which can 
be modulated for experimental or therapeutic purposes. There is evidence that the 
modulation of the endocannabinoid system may also occur naturally as a result of the 
co-release of endogenous fatty acid derivatives such as PEA and OEA. These 
compounds can potentiate AEA effects and modulate endocannabinoid activity by 
competition at the receptors or by affecting substrate availability for metabolism (Di 
Marzo et al., 2005;Yazulla, 2008). Furthermore, the inhibition of AEA metabolism by 
FAAH blockers increases the sensitivity of CB1 or CB2 receptors for AEA (Di Marzo 
et al., 2005;Pertwee, 2005). 
 
1.4.1.1. Endocannabinoid Receptors 
Endocannabinoids act through two types of receptors: CB1 receptors, localized 
predominantly in the CNS (Pertwee, 1997;Rivers and Ashton, 2010), and CB2 
receptors, localized mostly in the peripheral nervous system and are associated with 
mechanisms of the immune response (Tomida et al., 2004;Rivers and Ashton, 2010).   
CB1 and CB2 receptors are Gi/o protein-coupled receptors that modulate the 
activity of several plasma membrane proteins and intracellular signaling pathways 
(Hernangómez et al., 2014). Activation of both cannabinoid CB1 and CB2 receptors, 
and the subsequent stimulation of Gi/o heterotrimeric proteins, leads to inhibition of 
adenylate cyclase (AC), and consequently to the inhibition of the protein kinase A 
(PKA) phosphorylation, or to stimulation of mitogen-activated protein kinase (MAPK)  
(Di Marzo et al., 2004) (Fig. 11). 
There are studies suggesting that CB1 receptors affect different cellular functions 
depending if they are short-term or long-term activated. In one hand, activation for 
seconds of neuronal CB1 receptors inhibits presynaptic voltage-activated calcium 
channels and activates inwardly rectifying potassium channels, reducing 
neurotransmission (Di Marzo et al., 2004;Hernangómez et al., 2014). On the other 
hand, CB1 receptor activation for minutes to hours alter gene expression, for 
example, inducing the expression of neuroprotective proteins, such as brain-derived 
neurotrophic factor (BDNF), known to counteract cell damage (Hernangómez et al., 
2014) (Fig. 11).  
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Figure 11 – CB1 and CB2 receptors. CB1 and CB2 receptors are Gi/o protein-coupled receptors 
that when activated inhibit AC, thus modulating PKA phosphorylation or stimulating MAPK. AC - 
adenylate cyclase; PKA - protein kinase A; MAPK - mitogen-activated protein kinase (adapted from 
(Di Marzo et al., 2004)). 
 
1.4.2. Endocannabinoid System in the Eye 
In the eye, marijuana and cannabinoids consumption produces hyperemia, due to 
local vasodilation, decreases intraocular pressure and changes retinal synaptic 
signalling (Yazulla, 2008;Slusar et al., 2013). Furthermore, the presence of a functional 
endocannabinoid system localized in ocular tissues has been established (Hu et al., 
2010), and AEA and 2-AG have been detected in various ocular tissues, including 
retina (Yazulla, 2008). Also, the presence of the FAAH enzyme has been described in 
several structures of the eye, namely in the retina, choroid, iris, optic nerve and 
lacrimal gland (Matsuda et al., 1997;Yazulla et al., 1999). Moreover, as in the other 
tissues, FAAH in the eye is thought to be the primary mediator of the hydrolysis of 
released endocannabinoids (AEA, OEA and PEA). Enhancement of endocannabinoid 
responses can be achieved with inhibition of FAAH activity. 
In the eye, CB1 receptors are expressed in the ciliary body, iris, trabecular 
meshwork, and retina, mainly in the INL and GCL (Straiker et al., 1999;Zhong et al., 
2005;Bouskila et al., 2012). The ocular hypotensive effects of endocannabinoids might 
be related to their action on CB1 receptors present in eye structures. However, it 
was also described the presence of CB2 receptors in the trabecular meshwork and 
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its involvement in the IOP reduction mediated by endocannabinoids (Zhong et al., 
2005).  
In summary, the endocannabinoid system has a role in ocular function and several 
findings have prompted considerable research into the therapeutic potential of 
targeting the endocannabinoid system for the treatment of a number of degenerative 
ocular diseases, including glaucoma (Nucci et al., 2008). 
 
1.4.3. URB597 and FAAH enzyme 
The FAAH inhibitor URB597 is carbamate inhibitor, which displays an excellent 
selectivity for FAAH in the nervous system, although the inhibitor does inactivate 
additional peripheral hydrolases (Mileni et al., 2010). Furthermore, URB597 binds in 
the hydrophobic and catalytic core of FAAH that connects the active site residues to 
the membrane surface of FAAH (Mor et al., 2004). It is describeb that URB597 
reduces the expression of the LPS-induced enzymes cyclo-oxygenase 2 (COX-2) and 
iNOS in primary rat microglial cells, with a concomitant reduction in the release of 
the inflammatory mediators prostaglandin E2 (PGE2) and NO (Tham et al., 2007). 
Moreover, in vivo studies, URB597 inhibits anandamide hydrolysis in rat brain 
membranes and in parallel increase AEA, OEA and PEA levels in brain, by inhibition 
of FAAH (Fegley et al., 2005). In addition, URB597 reduces allodynia and hyperalgesia 
through CB1 and CB2 receptors mediated analgesia in rats with inflammatory pain 
(Jayamanne et al., 2006). 
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2. Aims 
Glaucoma is a multifactorial neurodegenerative disease with complex genetic and 
environmental factors (Baltmr et al., 2010), and elevated IOP is considered the major 
risk factor to develop glaucoma. In addition, growing evidence also indicates that 
neuroinflammation has a role in the pathophysiology of glaucoma, which is 
characterized by an increase in microglial reactivity and in the release of pro-
inflammatory mediators (Madeira et al., 2015a). All this together leads to damage of 
the optic nerve and loss of RGCs. 
Both increased levels of FAAH enzyme, which degrades AEA, and elevated 
glutamate levels in the retina were reported in an acute experimental model of ocular 
hypertension (Nucci et al., 2007). Moreover, increasing AEA levels, by inhibiting 
FAAH, reduced retinal damage in a model of optic nerve axotomy (Slusar et al., 2013). 
Taken together, these evidences suggest that increasing local endocannabinoid levels, 
particularly AEA, may be an effective supplement to the arsenal of neuroprotective 
strategies for retinal neurodegenerative diseases, such as glaucoma. Moreover, taking 
into account the ocular hypotensive properties of endocannabinoids, in addition to 
its neuroprotective and anti-inflammatory effects, FAAH inhibitors have the potential 
to decrease IOP, thereby strengthening its relevance to treat glaucoma, protecting 
RGCs against degeneration.  
One of the main goals of this project was to investigate for the first time the 
potential neuroprotective and anti-inflammatory effects of a FAAH inhibitor 
(URB597) in a model of EHP in rat retinal explants. Our preliminary results indicated 
that exposure of retinal explants to EHP increased endocannabinoids levels. Another 
goal was to assess the potential effect of URB597 in decreasing IOP in a model of 
ocular hypertension. 
URB597 is a selective FAAH inhibitor with described neuroprotective and anti-
inflammatory properties in only two studies in animal models: optic nerve axotomy 
model (Slusar et al., 2013) and ischemia reperfusion model (Nucci et al., 2007), which 
are not chronic glaucoma models.  Therefore, the potential role of this compound in 
decreasing IOP in an animal model of hypertension is not clarified. In order to 
accomplish our goals, and to clarify whether the observed effects are mediated by CB1 
receptors activation by increased endocannabinoids levels, URB597 administered in 
the absence or presence of CB1 antagonist (O-2050) to animals submitted to EVC, to 
evaluate its effect on IOP. Similarly, retinal explants were challenged with EHP and 
were pre-incubated with URB957, in the absence or presence O-2050. In retinal 
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explants, it was evaluated FAAH activity, levels of endocannabinoids, alterations in 
the morphology of microglial cells, iNOS expression in microglia, nitric oxide and 
pro-inflammatory cytokines production, and RGC death. 
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3. Methods 
 
3.1.1.  Animals 
Male Wistar Han rats were housed under controlled environment (22 ± 0.1ºC of 
temperature, 67.6±1.6% of relative humidity, 12 h-light/dark cycle) and were maintained 
in a food and water ad libitum regime. 
All procedures involving animals were in accordance with European Community 
guidelines for the use of animals in laboratory (Directive 2010/63/EU) and in 
accordance with the “Association for Research in Vision and Ophthalmology (ARVO)” 
rules for the use of animals in ophthalmology and vision science experimentation. 
 
3.1.2.  Retinal Organotypic Cultures 
Animals aged 8-10 weeks were sacrificed by cervical dislocation. The eyes were 
enucleated and dissected in sterile Ca2+- and Mg2+-free HBSS (in mM: 132 NaCl, 5.4 
KCl, 0.45 KH2PO4, 0.45 Na2HPO4, 4 NaHCO3, 2.8 glucose, 5 HEPES, pH 7.3). The 
obtained retinal explants were flat-mounted onto 30 mm diameter culture plate 
inserts with a 0.4 μm pore size (Millicell, Millipore, USA), with the GCL facing up (Fig. 
12). Explants were then cultured in 6-well plates containing Dulbecco’s modified Eagle 
medium: Nutrient Mixture F-12 (DMEM/F-12) medium containing GlutaMAX I (Life 
Technologies, USA), supplemented with 10% fetal bovine serum (FBS; Life 
Technologies, USA) and 0.1% gentamicin (Life Technologies). Retinal explants were 
maintained for 3 days in vitro (DIV) in a humidified incubator at 37°C with 5% CO2. 
At DIV1 and DIV2, culture medium was replaced with fresh medium. 
 
Figure 12 - Retinal organotypic culture at DIV0 with the RGC facing up.  
 
3.1.3. Drug Exposure to Retinal Organotypic Cultures 
Retinal explants were incubated at DIV2 with 10 µM URB597 (FAAH inhibitor; 
Sigma-Aldrich, USA). After 1 h of incubation, retinal explants were exposed to EHP 
(+70 mmHg above atmospheric pressure; Fig. 13) for 24 h. In some retinal explants, 
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a pre-treatment with 10 μM O-2050 (CB1 receptor antagonist; Tocris, UK), was 
applied 15 min before incubation with URB597 (Fig. 14).  
 
Figure 13 – Pressure chamber. Humidified pressure chamber, equipped with a regulator to ensure 
+70 mmHg, placed inside an oven at 37ºC.  
 
 
Figure 14 - Schematic representation of drug exposure in retinal explant cultures. 
 
3.1.4. Immunohistochemistry 
Retinal explants were washed three times with warmed phosphate buffered saline 
(PBS, in mM: 137 NaCl, 2.7 KCl, 10 Na2HPO4, 1.8 KH2PO4, pH 7.4) solution and fixed 
with ice-cold 100% ethanol for 10 min at 4ºC. Explants were washed again with PBS, 
and non-specific binding was prevented by incubation with 3% bovine serum albumin 
(BSA), 10% normal goat serum (NGS), and 0.1% Triton X-100, in PBS, for 1 h at room 
temperature (RT). Samples were then incubated with primary antibodies (Table 1) in 
blocking solution for 48 h at 4ºC. After being washed several times with PBS, explants 
were incubated with secondary antibodies (Table 1) overnight (o.n.) at 4ºC in the 
dark. Then, explants were extensively washed with PBS and incubated with DAPI 
(1:1000; Life Technologies, USA) for 15 min in the dark to stain nuclei. After washing, 
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explants were flat-mounted on glass slides with the GCL facing upwards and 
coverslipped with Glycergel mounting medium (Dako, Denmark). The images were 
acquired in a laser scanning confocal microscope LSM 710 (Zeiss, Germany). 
 
 
Table 1 – List of primary and secondary antibodies used in the immunohistochemistry 
 Supplier (cat no) Host Dilution 
Primary Antibodies 
Anti-Brn3a Chemicon (MAB1585) Mouse 1:500 
Anti-CD11b Serotec (MCA275G) Mouse 1:100 
Anti-iNOS Santa Cruz Biotechnology  
(NOS2M-19) 
Rabbit 1:200 
Secondary Antibodies 
Alexa Fluor® 488 Anti-
Rabbit IgG 
Invitrogen (A11008) Goat 1:200 
Alexa Fluor® 568 Anti-
Mouse IgG 
Invitrogen (A11004) Goat 1:200 
 
 
3.1.5.  TUNEL Assay  
TdT-mediated dUTP nick-end labeling (TUNEL) assay was performed according to 
instructions provided by the manufacturer (Promega, USA). 
Retinal explants were fixed with ice-cold 100% ethanol for 10 min at 4ºC, and then 
hydrated twice with PBS. Samples were permeabilized with 20 μg/mL proteinase K 
for 15 min at RT, followed by incubation with equilibration buffer (200 mM potassium 
cacodylate, 25 mM Tris-HCl, 0.2 mM DTT, 0.25 mg/mL BSA and 2.5 mM cobalt 
chloride) for 10 min. Explants were then incubated with the recombinant TdT enzyme 
and nucleotide mix containing dUTP conjugated with fluorescein, at 37°C for 1 h. The 
reaction was stopped by incubating the explants in saline-citrate buffer for 15 min at 
RT and then washed three times for 5 min with PBS. The nuclei were stained with 
DAPI (1:1000; Life Technologies). After washing, retinal explants were flat-mounted 
on glass slides with the GCL facing upwards and coverslipped with Glycergel 
mounting medium (Dako). The images were acquired in a laser scanning confocal 
microscope LSM 710 (Zeiss). 
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3.1.6. Image Analysis 
Immunostained retinal explants were examined in a Zeiss LSM 710 confocal 
microscope. For each condition, 4 images per quadrant, in a total of 16 images, were 
acquired randomly with a Plan-Apochromat 20x/0.8 M27 objective lens. In order to 
compare the different conditions, all images were acquired using the same gain and 
exposure settings.  
 
Densitometric analysis was performed for iNOS/CD11b stained cells using the 
public domain ImageJ program (http://rsb.info.nih.gov/ij/). The immunoreactivity of 
each cell was calculated using the following formula, as previously described (Gavet 
and Pines, 2010): 
Corrected total cell fluorescence = Integrated density – (Area of selected cell x Mean 
fluorescence of background readings). 
 
To assess differences in microglial morphology, the particle measurement feature 
in ImageJ was used to calculate the 2D area, perimeter, circularity, and Feret’s 
diameter of each microglial cell present in each image collected. As previously 
described (Kurpius et al., 2006), threshold was uniformly set to outline microglial cells 
and the four parameters were then automatically measured. Circularity was evaluated 
using the following formula: 
circularity = 4π(area/perimeter2) 
A circularity value of 1.0 indicates a perfect circular cell, and as the value 
approaches 0, it indicates increasingly ramified cells. Feret’s diameter is a measure of 
the cell’s length. It represents the longest distance between any two points along the 
selection boundary. 
 
3.1.7. Endocannabinoid Levels in Retinal Explants 
The levels of the endocannabinoids anandamide (AEA), oleoylethanolamide (OEA), 
and palmitoylethanolamide (PEA) in retinal organotypic cultures were analyzed by 
liquid chromatography coupled with tandem mass spectrometry (LC-MS/MS) at BIAL 
laboratories. Samples were collected and immediately stored at -80ºC, and then 
shipped to BIAL for posterior analysis. 
 
Sample preparation for LC-MS/MS analysis  
Frozen explants previously weighed were homogenized in 500 μL of 
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chloroform:methanol (2:1) and 500 μL of 0.1 M phosphate buffer, pH 5.6. Tissue 
homogenates were spiked with 1 μL of 125 μg/mL internal standard (AEA-d8, PEA-
d4, OEA-d2). Samples were then subjected to chloroform:methanol extraction. After 
centrifugation, the organic layer was carefully removed and transferred to a plastic 
vial. The aqueous layer was re-extracted with 500 µL of chloroform:methanol (2:1). 
This procedure was repeated twice and the organic layer was combined and 
evaporated in a speed-vacuum at 35°C to dryness. The samples were reconstituted 
with 100 μL of acetonitrile and injected into LC-MS/MS to measure the fatty acids.  
 
 
3.1.8. Evaluation of FAAH Activity in Retinal Explants 
FAAH activity in retinal explants was also measured at BIAL laboratories. Retinal 
explants were collected in vials containing 750 µL of membrane buffer (3 mM MgCl2, 
1 mM EDTA, 50 mM Tris-Cl, pH 7.4). Samples were stored immediately at -80 °C 
and then shipped to BIAL for posterior analysis. 
 
Sample preparation 
Frozen explants previously weighed were homogenized with homogenizer 
Precellys 24 (Bertin, France) using ceramic beads. Total protein content in tissue 
homogenates was determined with the BioRad protein assay (BioRad, USA) using a 
standard curve of BSA (50-250 µg/mL). 
 
Reagents and solutions 
Anandamide [ethanolamine-1-3H, AEA] was obtained from American 
Radiochemicals with a specific activity of 60 Ci/mmol (batch 140320). All other 
reagents were obtained from Sigma-Aldrich. Optiphase Supermix was obtained from 
Perkin Elmer. 
 
FAAH activity determination 
Reaction mix (total volume of 200 µL) contained: the substrate AEA (ratio cold:hot 
400:1, 2 µM AEA + 5 nM 3H-AEA), 0.1% fatty acid free BSA, 60 µg protein, in 1 mM 
EDTA, 10 mM Tris, pH 7.6. After 15 min of pre-incubation at 37°C the reaction was 
started by the addition of the substrate solution (cold AEA + radiolabelled AEA + 
BSA). The reaction was carried out for 25 min at 37°C and terminated by addition of 
400 µL activated charcoal suspension (8 g charcoal in 32 mL 0.5 M HCl in continuous 
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agitation). After a 30 min incubation period at RT with agitation, charcoal was 
sediment by centrifugation in a microfuge (10 min at 13000 rpm). Then, 200 µL of 
supernatants were added to 800 µL Optiphase Supermix scintillation cocktail 
previously distributed in 24-well plates. Counts per minute (CPM) were determined 
in a Microbeta TriLux scintillation counter (PerkinElmer, USA) (10 min counting). In 
each assay, blank samples (without protein) were prepared. 
 
3.1.9. Animal Training and Handling 
The values of IOP may vary due to several factors, such as the time of the day 
(Gelatt and MacKay, 1998), animal stress (Miyazaki et al., 2000), and anesthesia 
(Murphy, 1985). Therefore, to reduce the stress of animals and the potential effects 
of anaesthetics on IOP, all animals were handled to become accustomed to the 
researcher and to the tonometer. A training paradigm was implemented, which 
consisted in the following protocol: before starting the experiments, animals were 
trained for 2 weeks. During the first 3 days, the animals were acclimatized to the 
experimental room and to the technician who handled the animals. Also, animals were 
habituated to corneal touch (technician fingers, with gloves). In the following days, 
the animals were accustomed to IOP measurements with the Tonolab tonometer 
(iCare, Finland). Animals were also accustomed to restraint for drug administration. 
In the period of handling and training, several factors were taken into account: the 
training/measurements were performed in the same period of the day (to avoid 
circadian variations in IOP); before handling the animals, they were acclimatized to 
the room for 15-20 min; between each measurement the benches were cleaned with 
70% ethanol; the animal bedding was changed twice a week, but only after the 
training/measurements; the animals were weighed every week and 1 or 2 days before 
the experiments.  
 
3.1.10. IOP Measurements 
IOP was measured with the Tonolab tonometer. This tonometer was specially 
designed to measure IOP in rodents (Morrison et al., 2009). In order to decrease 
variability and increase IOP measurement confidence, 10 IOP readings were 
performed for each eye, always starting by the right eye. IOP measurements were 
performed immediately before drug administration and at the timepoints indicated in 
the figure 16.  
The IOP measurements of the last 3 days of training were considered as basal 
values of reference. 
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3.1.11. Animal Model of Ocular Hypertension 
After two weeks of animal training, ocular hypertension was induced in animals, 
by decreasing the outflow of aqueous humour from the anterior chamber. This was 
achieved by episcleral vein cauterization (Shareef et al., 1995;Urcola et al., 2006). Both 
eyes of each animal were submitted to interventions. 
Animals were anesthetized with 2.5% isoflurane (Abbott Laboratories, USA), and 
4 mg/mL oxybuprocaine (Anestocil, Edol) was topically applied in the eye to minimize 
animal distress. Episcleral veins were exposed by a conjunctival incision, after lateral 
canthotomy. Two of the episcleral veins that are dorsally positioned, near to the 
superior rectus muscle, and another vein that is temporally positioned close to the 
lateral rectus muscle, were isolated from the involving tissues (Fig. 15). Then, a low-
temperature ophthalmic cautery (World Precision Instruments, USA) was used to 
cauterize the veins, taking care to avoid damaging the surrounding tissue. In the final 
procedure, a viscous eye drops containing fusidic acid (10 mg/g, Fucithalmic, LEO 
Pharmaceuticals, Denmark) was applied.  
IOP was measured before (basal values) and daily after the procedure. Only the 
eyes with an IOP above 16 mmHg and with 30% increase above basal IOP values were 
considered with ocular hypertension and were used in the subsequent experiments. 
 
 
Figure 15 - Scheme of the episcleral vein localization in the eyeball. A1, B1, and C1: episcleral veins 
before cauterization; A2, B2, and C2: episcleral veins after being cauterized. SR- superior rectus 
muscle; LR - lateral rectus muscle; SO - superior oblique muscle; IO - inferior oblique muscle; IR - 
inferior rectus muscle and MR – medial rectus muscle (adapted from (Bai et al., 2014)). 
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3.1.12. Drug Preparation and administration to animals with or without 
ocular hypertension 
Stock solution of FAAH inhibitor, URB597, was prepared in dimethyl sulfoxide 
(DMSO), as indicated by the supplier, and kept at -20°C. URB597 and O-2050 
emulsion were prepared in Tocrisolve 100 (1:4 ratio of soya oil/water, which was 
emulsified with the block co-polymer, Pluronic F68; Tocris, UK) in the day of the 
experiment.  
URB597 and O-2050 were administered separately by intraperitoneal injection 
(i.p.) in the dose of 10 mg/kg and 1 mg/kg, respectively. Control animals received a 
single i.p. injection of vehicle (Tocrisolve). 
Animals were randomly divided into 7 experimental groups, 4 groups with elevated 
IOP and 3 groups without elevated IOP. IOP was measured immediately before drug 
administration (t=-2 h). URB597 or vehicle (Tocrisolve) were administered (i.p.) at 
the initial time point (t=-2 h). O-2050 or vehicle were administered (i.p.) 1 h after 
URB597 administration, at t=-1 h. IOP was measured after drug administration at the 
following timepoints: t=0 h, t=2 h and t=3 h (Fig. 16). 
 
Figure 16- Scheme of drug administration and IOP measurements. 
 
3.1.13. Statistical Analysis 
Results are presented as mean ± standard error of the mean (SEM). Statistical 
analysis was performed using GraphPad Prism (GraphPad Software, USA). Differences 
were considered statistically significant for p<0.05. 
In the results obtained from tasks using retinal explants, parametric One Way 
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ANOVA test was used, followed by Holm-Sidak’s multiple comparison test.  
To analyse differences in IOP between control and EVC animals, until 7 days of 
inducing elevated IOP by episcleral vein cauterization, the statistical significance was 
evaluated with parametric Two Way ANOVA test, followed by Sidak’s multiple 
comparisons test. 
In tasks using animals administrated with drugs, IOP values were normalized according 
to the following formula: 
IOP(𝑡𝑥) =
IOP(𝑡𝑥)−IOP(t𝑖)
IOP(t𝑖)
, ti = -2 h.   
In this case, the statistical significance was evaluated with parametric Two Way 
ANOVA test, followed by Tukey’s multiple comparison test, to compare the effects 
of drugs with the vehicle, as well as to compare the effects of drugs, at the same 
timepoint. To analyse the drug effect along time, Repeated Measurements One Way 
ANOVA was used, followed by Tukey’s multiple comparison test. 
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4. Results 
In the present work, one of the main goals was to evaluate whether URB597, a 
selective inhibitor of FAAH, could be able to decrease the IOP in an animal model of 
ocular hypertension. Therefore, 7 days after performing EVC in the animals, URB597 
was injected intraperitoneally. To evaluate whether the potential effect of URB597 could 
be mediated, at least partially, by CB1 receptors, in some experiments, O-2050, a CB1 
receptor antagonist, was administered (i.p.) 1 h after URB597. IOP was measured 
immediately before and 2 h, 4 h, and 5 h after URB597 administration. Another goal was 
to investigate whether URB597 could have neuroprotective and anti-inflammatory 
effects in rat retinal explants subjected to elevated hydrostatic pressure (EHP). As in 
the EVC animal model,  in retinal explants it was also intended to investigate whether the 
effects of URB597 could be mediated by CB1 receptor activation. For this purpose, 
retinal explants were challenged with EHP and were pre-incubated with URB957, in 
the absence or presence of O-2050. 
 
4.1. Effect of EVC on IOP 
IOP was measured during 7 days in control animals (without EVC) and in animals 
submitted to EVC (Fig. 17). After EVC procedure, there was a significant increase in 
IOP comparing to control animals, in all days analysed. At day 1, the IOP value in EVC 
animals was 17.7 ± 1.9 mmHg, significantly higher compared with control animals 
(13.5 ± 0.5 mmHg). At day 7, the IOP in EVC animals was 18.6 ± 0.6 and in control 
animals was 13.3 ± 0.6 mmHg. 
Figure 17 - EVC increases IOP for 7 days. In animals subjected to EVC, the cauterization was 
performed in both eyes. The data represent the average IOP values in each eye of 6 - 8 animals, in 
each day, during 7 days after EVC procedure. *p<0.05, ***p<0.001, and ****p<0.0001, significantly 
different compared with control, Two-way ANOVA followed by Sidak’s multiple comparisons test.  
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4.2. Effect of URB597 and O-2050 administration in IOP in animals 
with and without ocular hypertension 
It was evaluated the effect of URB597 (FAAH inhibitor) in IOP of animals submitted 
to EVC model, and if this effect would be mediated by CB1 receptor activation. 
It was observed that there were no significant changes with the vehicle treatment 
in animals with or without ocular hypertension (EVC model) (Fig. 18), in IOP along 
the several time points. Similarly, in control animals, URB597 (10 mg/kg, i.p.) or O-
2050 (1 mg/kg, i.p.) administration had no significant alterations in IOP along time (Fig. 
19). In animals with ocular hypertension, the administration of O-2050 did not alter 
IOP at the different time points (Fig. 20). However, URB597 treatment significantly 
decreased the IOP (Figs. 21 and 22) in animals with ocular hypertension at the time 
points t=2 h and t=3 h (p<0.05), as well as comparing with the control condition at 
the time points t=2 h (p<0.05) and t=3 h (p<0.01), and compared with the initial time 
point (t=-2 h), at t=2 h (p<0.01) and t=3 h (p<0.001). When the CB1 receptor 
antagonist, O-2050, was administered to animals with EVC that were pre-treated 
with URB597, the effect of URB597 was significantly inhibited at the time point t=3 h 
(p<0.05). Moreover, in the same group of animals, at the time point t=0 h, there was 
a significant decrease (p<0.05) of IOP compared with initial time point (t=-2 h), 
although this appears to be a common trend in all groups (Fig. 22).  
 
 
Figure 18 - Evaluation of the potential effect of vehicle administration in the IOP of 
animals with and without ocular hypertension (EVC model). Vehicle (Tocrisolve) was 
administered at t=-2 h and at t=-1 h. IOP was measured at the time points t=-2 h, t=0 h, t=2 h, and 
t=3 h. The results are expressed as mean ± SEM of the values calculated according to the formula 
described in the statistical analysis section. The number of animals is indicated between brackets. 
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Figure 19 - Evaluation of the potential effect of FAAH inhibitor, URB597, or CB1 receptor 
antagonist, O-2050, in the IOP of control animals with normal IOP. URB597 (10 mg/kg) or 
vehicle (Tocrisolve) were administered at t=-2 h, and O-2050 (1 mg/kg) or vehicle (Tocrisolve) were 
administered at t=-1 h. IOP was measured at the time points t=-2 h, t=0 h, t=2 h, and t=3 h. The 
results are expressed as mean ± SEM of the values calculated according to the formula described in 
the statistical analysis section. The number of animals is indicated between brackets.  
 
 
 
Figure 20 - Evaluation of the potential effect of CB1 receptor antagonist, O-2050, in the 
IOP of animals with ocular hypertension (EVC model). O-2050 (1 mg/kg) was administered at 
t=-1 h, and vehicle (Tocrisolve) was administered at t=-2 h and at t=-1 h. IOP was measured at the 
time points t=-2 h, t=0 h, t=2 h, and t=3 h. The results are expressed as mean ± SEM of the values 
calculated according to the formula described in the statistical analysis section. The number of animals 
is indicated between brackets. 
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Figure 21 - Evaluation of the effect of FAAH inhibitor, URB597, in the IOP of animals 
with ocular hypertension (EVC model). URB597 (10 mg/kg) was administered at t=-2 h, and 
vehicle (Tocrisolve) was administered at t=-2 h and at t=-1 h. IOP was measured at the time points 
t=-2 h, t=0 h, t=2 h, and t=3 h. The results are expressed as mean ± SEM of the values calculated 
according to the formula described in the statistical analysis section. The number of animals is indicated 
between brackets. *p<0.05, **p<0.01, compared with control; #p<0.05, compared with EVC; Two-
way ANOVA followed by Tukey’s multiple comparisons test. $$p<0.01 and $$$p<0.001, compared with 
t=-2 h; Repeated Measurements One Way ANOVA followed by Tukey’s multiple comparisons test. . 
 
Figure 22 - Evaluation of the effect of the CB1 receptor antagonist, O-2050, on the 
reduction of IOP triggered by the FAAH inhibitor, URB597, in animals with ocular 
hypertension (EVC model). URB597 (10 mg/kg) or vehicle (Tocrisolve) were administered at t=-
2 h and O-2050 (1 mg/kg) or vehicle (Tocrisolve) were administered at t=-1 h. IOP was measured at 
the time points t=-2 h, t=0 h, t=2 h, and t=3 h. The results are expressed as mean ± SEM of the values 
calculated according to the formula described in the statistical analysis section. The number of animals 
is indicated between brackets. #p<0.05, compared with EVC; +p<0.05, compared with EVC+URB597; 
Two-way ANOVA followed by Tukey’s multiple comparisons test. $p<0.05, $$p<0.01, $$$p<0.001, 
compared with t=-2 h; Repeated Measurements One Way ANOVA followed by Tukey’s multiple 
comparisons test. 
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4.3. URB597 inhibits FAAH activity in retinal explants 
The hydrolysis of endocannabinoids occurs mainly by FAAH, and enzyme that has 
been found in ocular tissues, including the retina (Matsuda et al., 1997;Yazulla et al., 
1999) . Since we aimed to evaluate the effect of FAAH inhibition on retinal explants, 
it was used URB597, a selective FAAH inhibitor (Slusar et al., 2013). Thus, it was 
measured the FAAH activity in control retinal explants and in retinal explants exposed 
to EHP, untreated or treated with URB597 (Fig. 23). In control, the FAAH activity 
was 19375 ± 1284 counts per minute (CPM). Exposure to EHP did not significantly 
alter FAAH activity (106.0 ± 3.8 % of control). As expected, in retinal explants treated 
with URB597, FAAH activity significantly decreased  to 0.09 ± 0.03% of control or 
0.17 ± 0.07% of EHP (p<0.0001). 
 
Figure 23 - URB597 inhibits FAAH activity in retinal explants. Retinal explants were cultured 
for 3 days and challenged, or not, with elevated hydrostatic pressure (EHP) at day 2 in culture, for 24 
h, in the absence or presence of 10 µM URB597 (FAAH inhibitor). The results are expressed in 
percentage of control as mean ± SEM. The number of independent experiments is indicated above the 
bars. ****p<0.0001, compared with control; ####p<0.0001, compared with EHP; One-way ANOVA 
followed by Holm-Sidak’s multiple comparisons test.  
 
4.4. URB597 increases endocannabinoids levels in retinal explants 
In mammals, AEA, PEA and OEA, are synthesized from glycerophospholipids and 
are degraded by FAAH (Ueda et al., 2013). Therefore, we aimed to evaluate whether 
the inhibition of FAAH by URB597, in retinal explants, as shown above, could increase 
the endocannabinoid levels in retinal explants exposed, or not, to EHP. 
In control condition, the AEA levels was 21.84 ± 2.51 ng/g (Fig. 24A). Exposure to 
EHP per se did not significantly alter AEA levels, (24.3 ± 3.09 ng/g). In retinal explants 
under normal pressure conditions treated with URB597, AEA levels increased 
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significantly to 530 ± 95.1 ng/g, comparing to control (p<0.01). In retinal explants 
challenged with EHP and treated with URB597 the AEA levels also significantly 
increased to 916.6 ± 170.8 ng/g, comparing with EHP (p<0.0001), and compared with 
URB597 condition (p<0.05). 
 
Figure 24 – URB597 increases the levels of endocannabinoids in retinal explants. The levels 
of AEA (A), OEA (B), and PEA (C) were measure in retinal explants cultured for 3 days and challenged, 
or not, with EHP, at day 2 in culture, for 24 h, in the absence or presence of 10 µM URB597 (FAAH 
inhibitor). The results are expressed as mean ± SEM. The number of independent experiments is 
indicated above the bars. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001, compared with control; 
#p<0.05, ##p<0.01, ###p<0.001, ####p<0.0001, compared with EHP; +p<0.05, compared with URB597; 
One-way ANOVA followed by Holm-Sidak’s multiple comparisons test. 
 
Relatively to OEA levels (Fig. 24B), in control the concentration was 203.6 ± 62.6 
ng/g. When explants were exposed to EHP, there was no significant alteration in OEA 
levels (327.1 ± 66.7 ng/g), similarly to what was found for AEA levels. Treatment with 
URB597 increased significantly OEA levels (5361 ± 1245 ng/g), comparing with the 
control (p<0.05). In explants exposed to EHP, URB597 also increased significantly 
OEA levels (9277 ± 1800 ng/g), comparing with explants in control condition 
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(p<0.001), exposed to EHP (p<0.001), and comparing with explants under normal 
pressure exposed to URB597 (p<0.05). 
Regarding PEA levels (Fig. 24C), in the control condition, the concentration was 
881.6 ± 270.9 ng/g. Exposure to EHP per se did not significantly alter PEA levels (1470 
± 286.6 ng/g), similarly to what happened with the other two endocannabinoids. In 
retinal explants under normal hydrostatic pressure conditions treated with URB597, 
PEA levels increased significantly (11665 ± 2337 ng/g), comparing with the control 
(p<0.01). In retinal explants challenged with EHP and treated with URB597, PEA levels 
also increased significantly (18251 ± 3103 ng/g), comparing with EHP (p<0.0001). 
Thus, in retinal explants, FAAH inhibition increases endocannabinoid levels.  
 
4.5. Evaluation of the effect of FAAH inhibitor on apoptotic cell death 
in retinal explants 
It was evaluated whether exposure of retinal explants to URB597 could induce 
cell death, particularly in the RGC layer. To accomplish this goal, was performed 
TUNEL assay in retinal explants (Fig. 25A). Was observed that URB597 (10 µM) did 
not significantly alters the number of TUNEL positive cells in RGC layer (136.6 ± 12.7 
% of control) compared with control. Thus, the inhibition of FAAH did not induce 
apoptotic cell death in the RGC layer.  
 
Figure 25 - Evaluation of the potential of URB597 to induce apoptotic cell death in retinal 
explants. Retinal explants were cultured for 3 days and challenged with 10 µM URB597 (FAAH 
inhibitor), at day 2 in culture. (A) Apoptotic cell death was assessed with TUNEL assay in RGC layer. 
Nuclei were counterstained with DAPI (blue) and representative imagesare depicted. Scale Bar: 50 
µm. (B) Quantification of TUNEL positive cells in RGC layer per field. The results are expressed in 
percentage of control as mean ± SEM. The number of independent experiments is indicated above the 
bars. 
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4.6. Effect of elevated hydrostatic pressure (EHP) in RGC survival 
The RGC survival was assessed by immunohistochemistry with an antibody that 
recognizes the transcription factor Brn3a, which is expressed only in RGCs in the 
retina and can be used to identify these cells (Nadal-Nicolas et al., 2009) (Fig. 26A).  
 
Figure 26 - Evaluation of the potential protective effect of the FAAH inhibitor, URB597, 
on RGC survival in retinal explants exposed to EHP. Retinal explants were cultured for 3 days 
and challenged with EHP, at day 2 in culture, for 24 h, in the absence or presence or of 10 µM URB597 
(FAAH inhibitor) and/or in the absence or presence of 10 µM O-2050 (CB1 receptor antagonist). (A) 
RGCs were identified by immunohistochemistry with an antibody against Brn3a. Nuclei were 
counterstained with DAPI (blue) and representative images are depicted. Scale Bar: 50 µm. (B) 
Quantification of the number of Brn3a-immunoreactive cells per field in each experimental condition 
indicated below bars. The results are expressed in percentage of control as mean ± SEM. The number 
of independent experiments is indicated above the bars. *p<0.05, compared with Control, One-way 
ANOVA followed by Holm-Sidak’s multiple comparisons test. 
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Recent studies from our group demonstrated that exposure to EHP decreases RGC 
survival (Madeira et al., 2015b). In fact, in retinal explants challenged with EHP, it was 
also found there was a significant decrease (p<0.05) in the number of Brn3a+ cells to 
60.8 ± 7.3% of control (125.8±11.41 cells per field) (Fig. 26B). In retinal explants 
treated with URB597, RGC loss induced by EHP was less pronounced (76.57 ± 9.5% 
of control), and this decrease in RGCs was not significantly different from control. 
However, this partial protective effect induced by URB597 did not reach statistical 
significance comparing to the condition where retinal explants were challenged with 
EHP. When retinal explants were challenged with EHP, in the presence of CB1 
receptor antagonist, O-2050 (10 µM), there was also a decrease in the number of 
Brn3a+ cells (64.1 ± 4.2% of control, p<0.05), an effect similar to what was found 
when retinal explants were challenged with EHP (60.8 ± 7.3% of control). Moreover, 
the presence of O-2050 did not significantly affect the partial protective effect induced 
by URB597 against RGC death triggered by EHP, suggesting that the activation of CB1 
receptor apparently did not mediate the partial protective effect of URB597, but this 
issue needs to be clarified with additional experiments. 
 
 
4.7. Evaluation of the potential effect of FAAH inhibitor, URB597, in 
microglial morphology in retinal explants 
Microglial cells present a ramified morphology under physiological conditions, 
which is associated with a surveillance phenotype. Changes in tissue homeostasis may 
lead microglia to adopt a less ramified morphology, in agreement with a reactive 
phenotype (Kettenmann et al., 2011). In our group, it was demonstrated previously 
that EHP induces alterations in microglial morphology in retinal explants, switching 
to a more amoeboid-like morphology (Madeira et al., 2015b). Based on this evidence, 
it was investigated if the FAAH inhibitor, URB597, could modulate microglial 
reactivity induced by EHP in cultured retinal explants, by assessing morphological 
alterations after CD11b labelling (Fig. 27A). It was also aimed to evaluate whether the 
potential effect of URB597 on microglial cell morphology could be mediated by CB1 
receptor activation, incubating retinal explants with an antagonist of CB1 receptor, 
O-2050 (10 µM). In order to evaluate the changes in microglia morphology, was 
assessed four different morphological parameters in microglial cells: area, perimeter, 
circularity, and Feret’s diameter. 
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Figure 27 - Evaluation of the potential effect of FAAH inhibitor, URB597, in microglial 
morphology in retinal explants. Retinal explants were cultured for 3 days and challenged with 
EHP at day 2 in culture, for 24 h, in the absence or presence of 10 µM URB597 (FAAH inhibitor) 
and/or in the absence or presence of 10 µM O-2050 (CB1 receptor antagonist). Microglial cells were 
identified by immunocytochemistry with anti-CD11b. Nuclei were counterstained with DAPI (blue). 
Representative images are depicted in A. Scale Bar: 50 µm. Microglia area (B), perimeter (C), Feret’s 
diameter (D), and circularity index (E) were determined using ImageJ. The results are expressed as 
mean ± SEM. The number of independent experiments is indicated above the bars. 
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Unexpectedly, we could not observe any significant alterations in microglia 
morphology triggered by exposure to EHP (Fig. 27). Moreover, we did not detect any 
significant alteration in microglial cell area (Fig. 27B), perimeter (Fig. 27C), circularity 
(Fig. 27D), or Feret’s diameter (Fig. 27E) between the different conditions tested. 
These observations contrast with our previous studies, since EHP did not induce 
microglia morphological alterations.  
 
4.8. Evaluation of the potential effect of FAAH inhibitor, URB597, in 
microglial iNOS immunoreactivity in retinal explants 
The inducible nitric oxide synthase (iNOS) isoform is one of the enzymes 
responsible for the synthesis of NO and is typically expressed in response to cellular 
stress (Morris and Billiar, 1994). It has been shown that NO derived from iNOS plays 
a key role in causing tissue damage and inflammation. Moreover, iNOS may play 
essential roles in the degenerative mechanisms in acute glaucoma model (Cho et al., 
2011). Taking this into account, it was evaluated iNOS immunoreactivity (iNOS-IR) 
in microglial cells localized in the RGC layer of retinal explants, after 24 h exposure 
to EHP. Microglial cells were identified by CD11b immunostaining. In control 
conditions, iNOS-IR in microglial cells was barely detected (Fig. 28A). In explants 
exposed to EHP, iNOS-IR significantly increased (p<0.05), comparing to control. 
Then was evaluated whether FAAH inhibition could rescue the microglia phenotype 
triggered by EHP. When retinal explants were treated with URB597, the increase in 
iNOS-IR induced by EHP was completely inhibited (p<0.05, comparing with EHP). 
This observation suggests that the inhibition of FAAH activity was sufficient to 
prevent the iNOS increase induced by EHP. We assessed if the inhibitory effect 
caused by FAAH inhibition was mediated by CB1 receptor activation, by incubating 
retinal explants with an antagonist of CB1 receptors, O-2050 (10 µM). The incubation 
with O-2050 did not block the effect of URB597, suggesting that CB1 receptor was 
not involved in the inhibitory effect caused by URB597.  
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Figure 28 - Evaluation of the potential effect of FAAH inhibitor, URB597, O-2050, in 
microglial iNOS-IR in retinal explants. Retinal explants were cultured for 3 days and challenged 
with EHP at day 2 in culture, for 24 h, in the absence or presence of 10 µM URB597 (FAAH inhibitor) 
and/or in the absence or presence of 10 µM O-2050 (CB1 receptor antagonist). (A) Retinal explants 
were immunostained for CD11b and for iNOS. Nuclei were stained with DAPI (blue) and 
representative images are depicted. Scale Bar: 50 µm. (B) Densitometric analysis for iNOS-IR was 
determined using ImageJ. The results are expressed as mean ± SEM. The number of independent 
experiments is indicated above the bars. *p<0.05, compared with control; #p<0.05, compared with 
EHP; One-way ANOVA followed by Holm-Sidak’s multiple comparisons test. 
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5. Discussion 
Glaucoma refers to a group of disorders characterized by optic neuropathy with 
alterations at the ONH, namely excavation of the optic disc, and progressive loss of 
RGCs. There are several factors that have been associated with the development and 
progression of glaucoma, such as systemic hypertension, family history, cigarette 
smoking, among others. However, elevated IOP and age are considered the main risk 
factors to develop glaucoma (Madeira et al., 2015a;Van de Velde et al., 2015).  
There are several animal models of glaucoma, including genetic models (e.g. 
DBA/2J mice) and inducible models of IOP elevation such as: microbead injections in 
the anterior chamber (Sappington et al., 2010;Morgan and Tribble, 2015), saline 
injection in the episcleral veins (Morrison et al., 1997), and EVC (Shareef et al., 
1995;Urcola et al., 2006). Regarding the EVC model, it has been described that the 
sustained increase in IOP leads to RGC death and triggers an inflammatory response 
including microglial activation (Roh et al., 2012) (Hernandez et al., 2009). This model 
has proven to be a good model to evaluate drug effects on IOP (Urcola et al., 2006). 
Therefore, was choose this model and induced a sustained increase in IOP for seven 
days. 
Since elevated IOP is considered the main risk factor of glaucoma, some in vitro 
models have been developed, such as the EHP model, to try to unveil the mechanisms 
behind glaucomatous disease.  In previous studies in our group, exposure to EHP 
induced neuronal cell apoptosis, namely in RGCs, and glial cell activation (Madeira et 
al., 2015b). 
Pharmacological studies have shown the involvement of ocular CB1 receptors in 
the IOP reduction induced by cannabinoids (Tomida et al., 2004). Moreover, the 
anatomical distribution of cannabinoid receptors suggests a possible influence of 
endocannabinoids on trabecular and uveoscleral aqueous humour outflow and on 
aqueous humour production, thus affecting IOP (Tomida et al., 2004). In addition, in 
a model of ocular hypertension, the topical administration of WIN-55,212-2, a 
synthetic agonist of CB1 receptor, in the eye, decreased significantly the IOP which 
remained low during treatment (Hosseini et al., 2006;Nucci et al., 2008). 
The hydrolysis of endocannabinoids, such as AEA, 2-AG, OEA and PEA occurs 
mainly via FAAH. Thus, by inhibiting FAAH, the levels of endocannabinoids increase 
in the organism, which may influence IOP. URB597 is a selective FAAH inhibitor and 
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its effects do not seem to ever been investigated in the context of a model of 
glaucoma characterized by chronic hypertension. There are only two studies 
evaluating the effect of URB597 in animal models of retinal degeneration, namely an 
optic nerve axotomy model (Slusar et al., 2013) and an ischemia-reperfusion injury 
model (Nucci et al., 2007), showing neuroprotective and anti-inflammatory properties 
of URB597. Those two models are not chronic glaucoma models since there is not a 
sustained elevation of IOP. In our EVC model, URB597 significantly decreased IOP in 
animals with ocular hypertension. We aimed to understand which mechanism 
mediates the effect of URB597 on IOP, by evaluating the involvement of CB1 
receptors. For this propose, it was administered a CB1 receptor antagonist, O-2050, 
in animals with ocular hypertension and treated with URB597. The administration of 
O-2050 partially inhibited the effect of URB597 on IOP, indicating the involvement of 
CB1 receptor activation. A few studies corroborated our results. For instance, pre-
treatment with CB1 receptor antagonists prevented the IOP-lowering effects 
normally observed after the administration of the metabolically stable analogue of 
AEA, methanandamide (Pate et al., 1997), or with synthetic cannabinoids such as 
CP55,940 (Pate et al., 1998) and WIN-55,212-2 (Hosseini et al., 2006;Nucci et al., 
2008).  
In order to prove that URB597 inhibits FAAH activity in ocular tissues, was 
measured the FAAH activity in cultured retinal explants under normal hydrostatic 
pressure conditions or submitted to EHP. As expected, our results show that 
URB597 significantly inhibited FAAH activity in retinal explants exposed to normal 
pressure or EHP. In order to understand whether exposure to EHP could affect the 
levels of endocannabinoids, as well as whether the inhibition of FAAH could trigger 
an increase in the levels of endocannabinoids in the retina, we evaluated the levels of 
endocannabinoids (AEA, OEA, and PEA) in retinal explants exposed, or not, to EHP, 
and treated with URB597. Exposure of retinal explants to EHP for 24 h did not 
significantly affect the levels of endocannabinoids, at least for this period of exposure 
to EHP. However, it can be noticed that there was a tendency for an increase in all 
measured endocannabinoids (AEA, OEA, and PEA). This observation suggests that 
the retinal tissue appears to slightly respond to this stress condition by increasing 
endocannabinoids levels. It is likely that for another period of exposure to EHP, it 
was could detect significant differences. Incubation with URB597 increased AEA, 
OEA, and PEA levels, both in retinal explants exposed to normal pressure and 
exposed to EHP. Moreover, in retinal explants exposed to EHP treated with URB597, 
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the levels of endocannabinoids were even higher, comparing to explants exposed to 
EHP, thus suggesting that EHP indeed potentiates the accumulation of 
endocannabinoids in the retina. This is the first time that is shown that EHP can 
potentiate the accumulation of endocannabinoids in the retinal tissue. Similarly, Fegley 
and colleagues also showed that FAAH inhibition by URB597 elevates brain AEA and 
OEA levels and amplifies the pharmacological actions of these endocannabinoids by 
selectively targeting FAAH activity (Fegley et al., 2005). 
As previously mentioned, RGC death is a hallmark of glaucoma, in which several 
mechanisms might be involved. IOP is considered the main direct inducer of RGC 
stress and apoptosis. Recent studies in our lab described that exposure to EHP 
decreases RGC survival in retinal explants (Madeira et al., 2015b). The FAAH 
inhibitor, URB597, was shown to delay RGC death in an optic nerve injury animal 
model (Slusar et al., 2013). In addition, URB597 treatment prevented the increase in 
FAAH activity in the retina and RGC loss triggered by ocular ischemia, suggesting that 
reduced levels of AEA caused by enhanced FAAH activity might play a role in the 
RGC loss provoked by ischemia-reperfusion injury (Nucci et al., 2008). Based on 
these evidences, we hypothesized that URB597 could afford neuroprotection and 
prevent RGC death in retinal explants challenged with EHP. However, first was 
evaluated whether URB597 per se could induce cell death in RGC layer in retinal 
explants, and it was found that URB597 did not induce cell death. Then, was evaluated 
RGC survival in retinal explants exposed to EHP and treated with URB597. As 
expected, EHP significantly decreased the number of RGCs. Treatment with URB597 
induced a small protective effect, because in retinal explants exposed to EHP, in the 
presence of URB597, the number of RGCs did not significantly differ from control 
condition. Slusar and colleagues also found that URB597 protects RGCs in animals 
submitted to optic nerve injury. These authors also showed that the administration 
of a CB1 receptor antagonist, AM281, abolished the effect of URB597 (Slusar et al., 
2013). Thus, we also investigated if the partial protective effect of URB597 could be 
mediated by CB1 receptors. Unexpectedly, our results suggest that the activation of 
CB1 receptors did not mediate the protective effect of URB597 on RGC survival. We 
must emphasize that the model we used in these experiments may correspond to a 
more severe injury compared to the model used by Slusar and colleagues, since, in 
addition to RGC axotomy to isolate the retinas, the retinas are exposed to EHP. As 
a consequence, other receptors might be involved in the protective effect of URB597, 
which may explain no major contribution of CB1 receptor. Moreover, we used a 
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different CB1 receptor antagonist, O-2050, which is a neutral cannabinoid CB1 
receptor antagonist and has a higher affinity to CB1 receptor comparing with AM281, 
which is an antagonist/inverse agonist of CB1 receptors (Süudhof, 2008). Despite this, 
we cannot draw a final conclusion about our results. Additional experiments are 
necessary to increase the number of independent experiments. 
Neuroinflammation has been described as an important player in the pathogenesis 
of glaucoma, by activating glial cells that initiate an inflammatory response (Madeira et 
al., 2015a). Under glaucomatous conditions, retinal microglial cells present alterations 
in morphology, gene expression, proliferation and immune response, compatible with 
a reactive phenotype (Karlstetter et al., 2010;Madeira et al., 2015a). In the resting 
state, microglia actively survey their microenvironment with extremely motile 
processes and protrusions, having a ramified morphology (Kettenmann et al., 2011;Li 
et al., 2015). When a retinal insult occurs, microglial cells localized in RGC layer 
become activated, changing their morphology and becoming more amoeboid and less 
ramified (Karlstetter et al., 2010;Saijo and Glass, 2011). In our laboratory, we have 
demonstrated that EHP induces alterations in microglial morphology, in retinal 
explants, switching to a more amoeboid-like morphology (Madeira et al., 2015b). 
Herein, we investigated if URB597 could modulate microglial reactivity induced by 
EHP in cultured retinal explants, by assessing morphological alterations, using several 
parameters (area, perimeter, circularity, and Feret’s diameter). We also aimed to 
evaluate whether the potential effect of URB597 could be mediated by CB1 receptor 
activation. Unexpectedly, we did not find any evidence of morphological changes in 
retinal microglia, although in previous experiments these morphological changes were 
consistent. This unexpected result might be related with slightly different 
experimental conditions, as in this study retinal explants were 1 day less in culture 
than in the others studies developed in our laboratory. It has been described that 
with more days in culture retinal explants present more cell degeneration (Buonfiglio 
et al., 2014), and this is correlated with an increase in microglia activation. This might 
explain why we did not observe significant changes in microglia morphology. 
Nevertheless, there are two studies showing that microglia activation in mice retinal 
explants increases upon an insult, but without significant changes in cell ramification 
(Lee et al., 2008;Kettenmann et al., 2011), indicating that using microglia morphology 
as a single parameter to measure microglia activation is restrictive.  
The inducible isoform of NOS (iNOS) is one of the enzymes responsible for the 
production of NO and is typically expressed in response to cellular stress (Morris 
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and Billiar, 1994). It has been shown that NO derived from iNOS plays a key role in 
an acute glaucoma model, causing inflammation and tissue damage (Cho et al., 2011). 
Moreover, the activation of microglial cells leads to the production of pro-
inflammatory and cytotoxic factors like NO, both in vivo and in vitro (Kraft and Harry, 
2011). In vitro studies developed in our laboratory have shown that exposure to EHP 
significantly increases iNOS immunoreactivity (iNOS-IR), mainly in microglial cells, 
confirming that these cells are the main producers of NO under these conditions 
(Madeira et al., 2015b). Therefore, in this study, to evaluate retinal microglia reactivity 
we analysed iNOS-IR in microglial cells in retinal explants exposed to EHP. As 
expected, EHP increased iNOS-IR in retinal microglia localized in RGC layer. We 
then evaluated whether treatment with URB597 could inhibit the upregulation of 
iNOS in microglial cells. In fact, the inhibition of FAAH activity was sufficient to block 
the iNOS increase induced by EHP, indicating that endocannabinoids control 
microglia reactivity. However, the results failed to demonstrate that CB1 receptors 
activation was mediating the inhibitory effect of URB597, downregulating iNOS-IR. 
On the contrary, the application of O-2050 in retinal explants exposed to EHP 
appears to prevent the increase in iNOS-IR triggered by EHP, suggesting that CB1 
receptor activation, and not CB1 receptor inhibition, could be partly involved in the 
increase of iNOS-IR in microglial cells, as previously shown (Waksman et al., 
1999;Cabral et al., 2001). Thus, other receptors or mechanisms might be responsible 
for the effect URB597, this however needs to be clarified because our results are not 
conclusive and more experiments are needed. 
In summary, our results indicate that the selective FAAH inhibitor, URB597, 
decreases IOP in an animal model of ocular hypertension and this effect seems to be 
partially mediated by CB1 receptor activation. In in vitro studies, we also demonstrated 
that URB597 increases the levels of endocannabinoids (AEA, OEA, and PEA) in the 
retina, and inhibits the degeneration of RGCs and the upregulation of iNOS 
expression in retinal microglial cells induced by EHP. In some experiments, it appears 
that CB1 receptor activation mediates, at least partially, the effects of URB597, but 
this needs to be confirmed, because the results are not entirely conclusive. Despite 
this, FAAH enzyme might be considered a potential therapeutic target worth to 
investigate in the context of glaucoma, once FAAH inhibition has the potential to 
decrease IOP, control neuroinflammation, and afford neuroprotection to RGCs. 
Further studies must be performed to better understand the mechanisms by which 
URB597 is able to exert anti-inflammatory and neuroprotective actions.
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6. Conclusions  
According to the results obtained in this thesis, we demonstrated that: 
 The selective FAAH inhibitor, URB597, significantly decreases IOP in an 
animal model of ocular hypertension, and this effect seems to be partially 
mediated by CB1 receptor activation; 
 In retinal explants submitted to EHP, URB597 inhibits FAAH activity leading 
to the increase of the levels of endocannabinoids (AEA, OEA, and PEA); 
 In retinal explants challenged with EHP, URB597 inhibited RGC loss 
induced by EHP exposure. The activation of CB1 receptors does not seem 
to mediate the protective effect of URB597 on RGC survival; 
 URB597 inhibits the upregulation of iNOS immunoreactivity in microglial 
cells induced by EHP exposure in retinal explants. Again, the CB1 receptor 
does not seem to mediate the inhibitory effect of URB597. 
 
In summary, this study clearly shows that  FAAH enzyme represents a potential 
therapeutic target worth to investigate in the context of glaucoma, since FAAH 
inhibition has the potential to decrease IOP, control neuroinflammation, and afford 
neuroprotection against RGC degeneration. However, further studies must be 
performed to better understand the mechanisms by which URB597 is able to exert 
anti-inflammatory and neuroprotective actions. 
 
Future perspectives 
We will increase the number of independent experiments already performed in 
retinal explants exposed to EHP to clarify the effect of URB597 and CB1 receptors 
on retinal neuroinflammation and RGC protection, Moreover, it would be interesting 
to evaluate the expression and release of pro-inflammatory cytokines in retinal 
explants exposed to the same experimental conditions.  
It would be also interesting to extend the duration of the ocular hypertension 
model (EVC) up to 14 days, in order to assess the anti-inflammatory and 
neuroprotective potential of URB597 treatment.  
In addition, to better understand the modulation of the endocannabinoid system, 
we would like to evaluate the involvement of the CB2 receptors in the effects induced 
by URB597 treatment in both models, animals with ocular hypertension and retinal 
explants exposed to EHP.
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